A July 22 show-cause order told ovarian talc plaintiffs to explain why their claims should not be dismissed for inability to prove specific causation. Five days later Johnson & Johnson filed an 8-K committing $5.5 billion to a resolution conditioned on 95 percent participation. The JPML's own July 1 statistics report shows why a two-case evidentiary problem reaches an entire inventory: MDL 2738 holds 68,435 of the 203,915 pending federal MDL actions in the country.
On July 22, 2026, in the District of New Jersey, Magistrate Judge Rukhsanah L. Singh ordered ovarian talc plaintiffs to show cause why their remaining claims should not be dismissed for inability to prove specific causation. The order was entered in MDL No. 2738, the docket assigned to Judge Michael A. Shipp in Newark. Five days later Johnson & Johnson filed a Form 8-K that put a price on the position that order created: "The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028." Nothing has been approved. Judge Shipp has a hearing set for August 3 on how the bellwethers proceed.
The posture shift is narrow and total. Plaintiffs withdrew their specific-causation experts, Dr. Judith Wolf and Dr. Daniel L. Clarke-Pearson, in two bellwether cases. Specific causation is the element that ties one woman's ovarian cancer to one product she used. Without an expert to carry it, the two test cases had no route to a jury. The show-cause order then put that same question to the rest of the docket.
The reason a two-case evidentiary problem could reach an entire inventory at once is arithmetic, and the arithmetic sits in a public report. The Judicial Panel on Multidistrict Litigation statistics report, report date July 1, 2026, carries the MDL 2738 row verbatim: "Michael A. Shipp (U.S. District Judge) MDL -2738 IN RE: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation 68,435 71,121." The same report totals 203,915 pending actions across 162 dockets, before 140 transferee judges in 51 districts. Divide 68,435 by 203,915 and the answer is 33.6 percent. Re-summed against the report's own total, the District of New Jersey holds 84,129 pending actions, 41.3 percent of the national figure. One judge in Newark is the assigned transferee judge for a third of every pending federal MDL action in the United States.
Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.
Johnson & Johnson's litigation chief put the company's reading on the record. In Exhibit 99.1, the press release attached to the 8-K, Erik Haas, Worldwide Vice President of Litigation, said plaintiffs "effectively conceded their inability to prove specific causation by withdrawing their experts on the topic in two bellwether cases," and called what followed "a watershed moment." The same release calls the claims "premised on junk science" and describes a "meritless 15-year litigation." Those are the company's own public characterizations, made in a securities filing, not findings by any court. No plaintiff-side response appears in the record reviewed, and the release announces a proposed, conditioned resolution, not a payment. Across the docket, the plaintiffs' steering committee is working under a different instruction from Judge Shipp: state how it intends to proceed on bellwethers, on August 3.
The money path is conditioned, staged, and reversible. The 8-K makes the agreement contingent on the express participation of at least 95 percent of the remaining claims. Exhibit 99.1 sharpens that into a firm-level test, requiring "the participation of lead plaintiff firms in all ovarian talc litigation pending in state and federal court, representing at least 95% of the remaining claims," across roughly 76,000 remaining ovarian talc claims. Per-claim payments, not a lump fund. First payment capped at $3 billion in 2027. Nothing further due before 2028. Read next to the show-cause order, the structure is legible. The order is the pressure point. The number is the proposed, conditioned price of ending the inventory if the 95 percent threshold is met. If the 95 percent does not arrive, the order is still live and the dismissal question is still open. Exhibit 99.1 also notes the company previously settled about 95 percent of filed mesothelioma lawsuits and all state consumer protection claims, and that it retained the talc liabilities when Kenvue separated in August 2023.
August 3 is the next fight, and it is procedural rather than evidentiary. The steering committee either presents a bellwether plan without the experts it withdrew, or it presents participation math. Johnson & Johnson, last seen in salcedo-reduced-lifespan-damages absorbing a $45 million Cook County talc verdict that stacked a $30 million reduced-lifespan damages category on top of a wrongful death award, now faces the same claim inventory as a single arithmetic problem in one Newark courtroom. MDL 2738 also carries a reported final pretrial conference on November 5, which means the docket still holds a trial track nobody has formally abandoned.
The concentration that turned 68,435 filings into one institutional exposure is the same concentration that let one number reach all of them. Venue math cuts in both directions, and the direction is set by whichever side wins the evidentiary question first. Judge Shipp did not assemble that inventory. Transfer orders did, one docket at a time, over fifteen years, and the JPML report is the receipt. What happens on August 3 settles only the next step. Until 95 percent of the remaining claims signs on, the show-cause order is the only thing on that docket with teeth.
The Executive Briefing is six questions. It shows you exactly where the gaps are.
Take the Executive Briefing →Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.